ENTRY       D01206                      Drug
NAME        Febuxostat (JAN/USAN/INN);
            Uloric (TN);
            Feburic (TN)
PRODUCT     ULORIC (Cardinal Health)
            ULORIC (Takeda Pharmaceuticals America)
  GENERIC   FEBUXOSTAT (Alembic Pharmaceuticals Limited)
            FEBUXOSTAT (Alembic Pharmaceuticals)
            FEBUXOSTAT (American Health Packaging)
            FEBUXOSTAT (Ascend Laboratories)
            FEBUXOSTAT (DR REDDY'S LABORATORIES LIMITED)
            FEBUXOSTAT (Lannett Company)
            FEBUXOSTAT (Macleods Pharmaceuticals Limited)
            FEBUXOSTAT (NorthStar RxLLC)
            FEBUXOSTAT (NuCare Pharmaceuticals)
            FEBUXOSTAT (Solco Healthcare US LLC)
            FEBUXOSTAT (Sun Pharmaceutical Industries)
            FEBUXOSTAT (Viona Pharmaceuticals)
            FEBUXOSTAT (Zydus Lifesciences Limited)
FORMULA     C16H16N2O3S
EXACT_MASS  316.0882
MOL_WEIGHT  316.3748
CLASS       Cardiovascular agent
             DG01503  Xanthine dehydrogenase inhibitor
            Musculo-skeletal system agent
             DG03130  Xanthin oxidase inhibitor
REMARK      Therapeutic category: 3949
            ATC code: M04AA03
            Chemical structure group: DG02878
            Product (DG02878): D01206<JP/US> D11081<JP/US>
EFFICACY    Gout suppressant, Uric acid biosynthesis inhibitor, Xanthine oxidase inhibitor
  DISEASE   Gout [DS:H01532]
COMMENT     Management of hyperuricemia in patients with gout
TARGET      XDH [HSA:7498] [KO:K00106]
  PATHWAY   hsa00230(7498)  Purine metabolism
            hsa04146(7498)  Peroxisome
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             M MUSCULO-SKELETAL SYSTEM
              M04 ANTIGOUT PREPARATIONS
               M04A ANTIGOUT PREPARATIONS
                M04AA Preparations inhibiting uric acid production
                 M04AA03 Febuxostat
                  D01206  Febuxostat (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antigout Agents
              Febuxostat
               D01206  Febuxostat (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               394  Gout preparations
                3949  Others
                 D01206  Febuxostat (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01503  Xanthine dehydrogenase inhibitor
               DG02878  Febuxostat
                D01206  Febuxostat
             Musculo-skeletal system agent
              DG03130  Xanthin oxidase inhibitor
               DG02878  Febuxostat
                D01206  Febuxostat
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Oxidoreductases (EC1)
               Xanthine dehydrogenase/oxidase
                XDH
                 D01206  Febuxostat (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D01206
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D01206
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D01206
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D01206
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01503  Xanthine dehydrogenase inhibitor
               DG02878  Febuxostat
             Musculo-skeletal system agent
              DG03130  Xanthin oxidase inhibitor
               DG02878  Febuxostat
DBLINKS     CAS: 144060-53-7
            PubChem: 7848269
            ChEBI: 31596
            PDB-CCD: TEI
            LigandBox: D01206
ATOM        22
            1   C8x C    16.2448  -15.8562
            2   C8y C    16.2448  -17.2564
            3   C8y C    17.4603  -17.9563
            4   C8x C    18.6686  -17.2564
            5   C8y C    18.6686  -15.8562
            6   C8x C    17.4603  -15.1562
            7   C8y C    19.8816  -15.1570
            8   C3b C    17.4620  -19.3565
            9   O2a O    15.0325  -17.9569
            10  C1b C    13.8197  -17.2575
            11  C1c C    12.6075  -17.9582
            12  C1a C    11.3946  -17.2587
            13  C1a C    12.6082  -19.3584
            14  S2x S    21.2083  -15.5955
            15  C8y C    22.0380  -14.4677
            16  C8y C    21.2218  -13.3302
            17  N5x N    19.8877  -13.7548
            18  C1a C    21.6625  -12.0012
            19  C6a C    23.4381  -14.4761
            20  O6a O    24.1311  -15.6927
            21  O6a O    24.1455  -13.2676
            22  N3a N    17.4539  -20.7566
BOND        23
            1     9  10 1
            2     5   6 2
            3    10  11 1
            4     6   1 1
            5    11  12 1
            6    11  13 1
            7     5   7 1
            8     1   2 2
            9     3   8 1
            10    2   3 1
            11    7  14 1
            12   14  15 1
            13   15  16 2
            14   16  17 1
            15   17   7 2
            16   16  18 1
            17    3   4 2
            18   15  19 1
            19    2   9 1
            20   19  20 2
            21    4   5 1
            22   19  21 1
            23    8  22 3
///
